Limitless X Holdings Inc.

Limitless X Holdings Inc. is a U.S.-based consumer products and brand licensing company centered on nutritional supplements and related wellness products. Its business has included manufacturing and distributing licensed products under agreements tied to brands controlled by its CEO, with recent disclosures showing a narrower focus on the NZT-48 supplement line after other licensed product lines were discontinued.

−961,8 %

75,3 %

−4 872,1 %

−71,8 %

0.04

0.01

— Limitless X Holdings Inc.
%
Nutritional supplements70% Dietary and wellness supplement products sold under the company's branded and licensed portfolio.
Licensed consumer products20% Products manufactured and distributed under third-party or related-party brand licenses.
Royalty and licensing arrangements10% Revenue-linked commercialization rights and royalty economics tied to licensed brands.

The company sells to consumers seeking nutritional and wellness products, typically through branded consumer channels...

  • End consumersprimary

    Buy supplements such as NZT-48 for personal wellness, convenience, and brand appeal.

  • Brand licensorsprimary

    Provide product rights and receive royalties; they determine which products can be sold.

  • Retail and distribution channelssecondary

    Purchase or carry the company's consumer products to reach final shoppers.

The available filings do not disclose a meaningful country-by-country revenue split, so the business profile is best...

  • •United States is the primary operating and reporting base
  • •No country-level revenue split was disclosed in the excerpts
  • •Consumer product sales may be distributed through U.S. channels
  • •Geographic concentration increases dependence on U.S. demand and regulation

Recent disclosures suggest a strategy of narrowing the product portfolio and concentrating on the NZT-48 supplement...

01
Focus on core supplement productsshort-term

A narrower portfolio can improve execution, inventory control, and brand focus.

02
Rationalize licensing and royalty structureshort-term

Lower complexity may reduce disputes, cash leakage, and related-party friction.

The company faces concentration risk because its product set has been narrowed and its commercial rights depend on a...

high

Product concentration

The portfolio has been narrowed to NZT-48 and a limited set of remaining products.

Scope
Revenue and brand dependence on one core product line
Materiality
high
high

Related-party dependence

Key licenses and preferred stock holders are tied to the CEO or CEO-controlled entities.

Scope
Governance, pricing, and transaction fairness
Materiality
high
high

License and royalty risk

The company needs valid license rights to manufacture and distribute products.

Scope
Commercial rights and gross margin structure
Materiality
high
medium

Consumer demand and regulatory risk

Supplement sales depend on consumer acceptance and compliance with product rules.

Scope
Sales volatility, recalls, and marketing restrictions
Materiality
medium
Revenue recognition for product sales
Affects reported sales timing and net revenue
Royalty accruals and license obligations
Affects gross margin and accrued liabilities
Inventory returns and license termination accounting
Affects inventory, receivables, and settlement gains/losses
Preferred stock dividend accruals and waivers
Affects equity, liabilities, and related-party disclosures

Healthier Choices Management Corp.

HCMC · Tobacco Products

China Foods Holdings Ltd.

CFOO · Medicinal Chemicals & Botanical Products

GOLDENWELL BIOTECH, INC.

GWLL · Food and Kindred Products

LFTD PARTNERS INC.

LIFD · Pharmaceutical Preparations

HEALTHY CHOICE WELLNESS CORP.

HCWC · Retail-Grocery Stores

X4 Pharmaceuticals, Inc

XFOR · Biological Products, (No Diagnostic Substances)

: 28/04/2026